Measurement of S-phase fraction and ploidy in sequential fine-needle aspirates from primary human breast tumours treated with tamoxifen

Fernando, Indrajit; Titley, J. C.; Powles, T. J.; Dowsett, Mitch; Trott, P. A.; Ashley, S.; Ford, H. T.; Ormerod, M.G.

doi:10.1038/bjc.1994.475

Cited by 12 publications

(8 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The significant (P ϭ 0.0068) reduction in estrogen receptor expression that we observed for arzoxifene has also been reported for idoxifene (13) but not consistently for tamoxifen (12,55,56). We also observed that for those subjects not on hormone replacement therapy in the peribiopsy period, there were significant (P ϭ 0.009) differences in both absolute change and relative change for placebo (medians of 0%) versus arzoxifene (median 5% decreases).…”

supporting

confidence: 68%

Breast Cancer Chemoprevention Phase I Evaluation of Biomarker Modulation by Arzoxifene, a Third Generation Selective Estrogen Receptor Modulator

Fabian

Kimler

Anderson

et al. 2004

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Arzoxifene, a new selective estrogen receptor modulator with strong breast antiestrogen activity and absence of uterine agonist activity, was explored as a potential chemoprevention agent. We performed a multi-institutional evaluation of arzoxifene in women with newly diagnosed ductal carcinoma in situ or T1/T2 invasive cancer.Experimental Design: In a Phase IA trial, 50 pre-or postmenopausal women were randomized to 10, 20, or 50 mg of arzoxifene daily in the interval between biopsy and re-excision or were enrolled as no-treatment controls. In a Phase IB trial, 76 postmenopausal women were randomized to 20 mg of arzoxifene versus matched placebo. Serum specimens collected at entry and at re-excision were assayed for various hormones and growth factors. Tissue from biopsies (estrogen receptor ؉ and/or progesterone receptor ؉) and re-excision specimens was evaluated immunohistochemically for proliferation (Ki-67 by MIB-1 and proliferating cell nuclear antigen) and other biomarkers.Results: In both trials, increases in serum sex hormone binding globulin were noted, as were decreases in insulinlike growth factor (IGF)-I and the IGF-I:IGF binding protein-3 ratio (P < 0.007 versus control/placebo). For 45 evaluable women in Phase IA, decreases in proliferation indices were more prevalent for arzoxifene (particularly 20 mg) than for controls. For 58 evaluable women in Phase IB, a decrease in estrogen receptor expression for arzoxifene was observed compared with no change with placebo (P ‫؍‬ 0.0068). However, decreases in proliferation indices for arzoxifene were not statistically different from placebo, perhaps due to a confounding effect of stopping hormone replacement therapy before entry.Conclusion: Given the favorable side effect profile and the biomarker modulations reported here, arzoxifene remains a reasonable candidate for additional study as a breast cancer chemoprevention agent.

show abstract

supporting

confidence: 68%

Breast Cancer Chemoprevention Phase I Evaluation of Biomarker Modulation by Arzoxifene, a Third Generation Selective Estrogen Receptor Modulator

Fabian

Kimler

Anderson

et al. 2004

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…Other sampling errors may also lead to differences between these two techniques. Tumour (Remvikos et al, 1988;Fernando et al, 1994), and it has been suggested that the yield of samples in which SPF can be estimated may in fact be increased by using FNAB (Remvikos et al, 1989).…”

Section: Discussionmentioning

confidence: 99%

Comparison of MIB-1 proliferation index with S-phase fraction in human breast carcinomas

Ellis

Makris²,

Burton³

et al. 1996

Br J Cancer

Self Cite

View full text Add to dashboard Cite

Summary The MIB-l antibody has been raised against recombinant parts of the Ki-67 antigen and, unlike Ki-67, has wider application to routinely fixed specimens. The aim of this study was to compare the usefulness of MIB-l with S-phase fraction (SPF) as a measure of proliferation. A total of 75 patients with operable breast cancer were studied, 44 (median age 56 years) before any treatment and 31 (median age 68 years) after primary medical hormonal therapy. Sections from formalin-fixed paraffin-embedded tissue were stained with the MIB-1 antibody and a percentage score of positively stained cells obtained. SPF was measured by flow cytometry in fine-needle aspiration samples taken from the same lesion in each patient. Median MIB-1 score was 9% and median SPF was 1. 1%. A close correlation was found between MIB-1 score and SPF (rho = 0.59, P < 0.0001). There was a difference in the strength of the correlation found between the no treatment group and the treatment group, however, 95% confidence intervals for the rho values overlapped, indicating that there was no significant statistical difference. When analysed for ploidy status a correlation was found only in aneuploid tumours. MIB-l immunostaining can be used as an effective method of assessing proliferation in human breast carcinomas. This can be done using simple, widely available technology and provides the opportunity to perform large-scale retrospective analyses of archival material.

show abstract

“…For a good measurement of S-phase fraction (SPF), the CV should be Ͻ8% (28) and 10% is often taken as the cut-off value; a measurement above 10% is considered to be unreliable (for example, see Ref. 13). …”

Section: Flow Cytometrymentioning

confidence: 99%

“…We have previously demonstrated the suitability and reproducibility of flow cytometry for the estimation of S-phase in sequential samples from primary breast carcinomas (10,13). In this paper we report our use of this approach for assessing apoptosis in fine-needle aspirates (FNAs) from primary breast carcinomas.…”

mentioning

confidence: 97%

Analysis and sorting of apoptotic cells from fine-needle aspirates of excised human primary breast carcinomas

et al. 1998

View full text Add to dashboard Cite

Measurement of S-phase fraction and ploidy in sequential fine-needle aspirates from primary human breast tumours treated with tamoxifen

Cited by 12 publications

References 23 publications

Breast Cancer Chemoprevention Phase I Evaluation of Biomarker Modulation by Arzoxifene, a Third Generation Selective Estrogen Receptor Modulator

Breast Cancer Chemoprevention Phase I Evaluation of Biomarker Modulation by Arzoxifene, a Third Generation Selective Estrogen Receptor Modulator

Comparison of MIB-1 proliferation index with S-phase fraction in human breast carcinomas

Analysis and sorting of apoptotic cells from fine-needle aspirates of excised human primary breast carcinomas

Contact Info

Product

Resources

About